Edison Investment Research - Destiny Pharma (DEST) Destiny Pharma - Eyes on the Phase IIb prize

Report

Edison Investment Research

Sean Conroy

Destiny Pharma - Eyes on the Phase IIb prize

With the US Phase IIb study results now expected around mid-2020, we have examined the study design and our expectations for the results. Separately, we have looked beyond the current study and indication to the application of Destiny Pharmaâ€™s products in infections associated with biofilms. Our valuation is Â£70.2m, or 160p per share.

10/12/2019 16 EN

Underlying

Destiny Pharma

Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.

See profile

GB00BDHSP575 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Hybridan

Hybridan Small Cap Feast - 25 April 2024

25th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: Smart Metering Systems (SMS.L) has delisted from the AIM market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radical Limited for a consideration of a...

14m 14m 1 EN

New Street Research

Destiny - Making Positive Changes (Sponsored Research, TP £1.20, 12 pgs)

Last week, Destiny reported positive preclinical safety data for XF-73 Dermal, facilitating its progression to clinical evaluation in diabetic foot ulcer (DFU) & serious burn wound infections. We view XF-73 as bringing a novel approach to treating these serious conditions. The company is exploring partnering options for both the Nasal and Dermal formulations, with this likely to be the next catalyst, in our view. NTCD-M3 also continues to progress, with a change of CDMO and a move to a solid formulation. Destiny is funded through to Q1 2025. For access to our initiation (Aug-2023) and recent n...

EUR 4668.50

February 14, 2024 February 14, 2024 1 EN

Hybridan

Hybridan Small Cap Feast - 31 Jan 24

31st January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to ...

January 31, 2024 January 31, 2024 1 EN

Freelancer - AI to drive return to growth

Freelancer’s Q124 results were mixed. Operationally, the company is seeing rising demand for AI specialists as customers seek affordable ways to develop proprietary AI. Notably, in Enterprise, the company delivered a large-scale AI pilot for a tech giant, sourcing 20,000 freelancers in 24 hours across 52 languages. This impressive achievement could lead to a substantial multi-year contract. Major initiatives across Loadshift and Escrow with leading organisations are set to be deployed over the coming months, potentially catalysing performance and diversifying revenue streams. We revise our for...

1h / 7m 1h / 7m 1 EN

Toby Thorrington

Toby Thorrington

Renewi - Solid trading and better cash generation

Renewi’s FY24 trading update was in line with management’s expectations and its improved cash generation is reassuring for investors. Attention is now likely to turn the strategic review of the UK Municipals with management stating that they remain on track to update markets by the end of June. This could lead to an exit of key liabilities and leave Renewi as an attractive circular economy investment with strong market positions and organic growth plans, which should assist in generating value, including a potential re-rating of the shares.

1h / 10m 1h / 10m 1 EN

Richard Williamson

Richard Williamson

Filtronic - Agreement with SpaceX drives upgrades

Filtronic has signed a strategic partnership and commercial agreement with SpaceX which includes a production order worth £15.8m and warrants that could be exercised for up to 10% of existing share capital. Filtronic announced its first orders from SpaceX in January 2023, although the customer was unnamed at that point. Since then, SpaceX has placed orders totalling $43m (including yesterday’s order) for products to support the build out of its Starlink low Earth orbit (LEO) satellite constellation. The scale of these orders is such that we upgrade our forecasts, with the larger impact on FY25...

2h / 43m 2h / 43m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN